A jury in the United States ruled that Apple must pay a record sum of $5.7 billion after establishing that it infringed on patents belonging to the audio company Taction Technology, which relate to haptic feedback technology. However, the jury did not conclude that Apple intentionally infringed the patents.
Taction Technology filed a lawsuit against Apple in 2021, claiming that Apple violated two patents owned by Taction related to haptic feedback systems. This technology allows devices to convey physical sensations to users through vibrations and is used, in particular, in smartphones and smartwatches.
Taction asserted that Apple used its inventions without obtaining a license or permission, and that improvements to vibration technology in Apple's products enhanced user interaction with the company's products.
Apple disagreed with the jury's decision and announced plans to appeal the verdict. The company emphasized that its Taptic Engine system is fundamentally different from Taction's technology, and that tests conducted by Taction during the proceedings confirm this.
The Taptic Engine system first appeared in the Apple Watch in 2014. Since then, Apple has continued to develop this technology and expand the capabilities of haptic feedback in its devices. Taction reported that the patents granted to the company in 2020 cover technologies that Apple used in its devices after their further development.
In 2023, a judge in San Diego ruled that Apple had not infringed Taction's patents. After an appeal of this decision, the case was sent for a new trial. In September, a jury trial took place in the U.S. District Court for the Southern District of California, which ruled in favor of Taction.
Haptic feedback has become a widespread technology in modern electronics. Small vibration motors in smartphones, watches, and game controllers respond to specific electronic signals, allowing users to receive physical confirmation of their actions.
The Taction case became one of several major patent disputes in which Apple defended its technologies. Furthermore, in November 2025, the court ordered the company to pay the medical technology enterprise Masimo $634 million in a case concerning the infringement of a patent related to blood oxygen level measurement technology.

